GeneDx Holdings Corp.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.4M | $102.3M | $121.0M | $116.7M | $102.7M | $87.1M | $95.6M | $76.9M |
| Cost of Revenue | $36.2M | $34.0M | $36.7M | $32.2M | $31.8M | $28.6M | $29.4M | $29.0M |
| Gross Profit | $78.2M | $68.2M | $84.3M | $84.5M | $70.9M | $58.5M | $66.2M | $47.8M |
| Gross Margin | 68.4% | 66.7% | 69.6% | 72.4% | 69.0% | 67.1% | 69.2% | 62.2% |
| Operating Expenses | ||||||||
| Research & Development | $19.7M | $19.8M | $24.5M | $19.8M | $15.1M | $12.6M | $11.6M | $11.7M |
| SG&A Expense | $76.0M | $74.6M | $9.1M | $44.4M | $46.9M | $50.5M | $28.1M | $26.9M |
| Operating Income | $-17.5M | $-57.5M | $-14.2M | $-3.3M | $9.0M | $-4.6M | $8.8M | $-7.8M |
| Operating Margin | -15.3% | -56.2% | -11.8% | -2.8% | 8.7% | -5.2% | 9.2% | -10.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-18.3M | $-62.4M | $-18.2M | $-7.4M | $10.6M | $-6.1M | $5.4M | $-8.4M |
| Income Tax Expense | $-518.0K | $897.0K | $-564.0K | $247.0K | $-246.0K | $447.0K | $-24.0K | $-47.0K |
| Net Income | $-17.7M | $-63.3M | $-17.7M | $-7.6M | $10.8M | $-6.5M | $5.4M | $-8.3M |
| Net Margin | -15.5% | -61.9% | -14.6% | -6.5% | 10.5% | -7.5% | 5.7% | -10.8% |
| EPS (Basic) | $-0.60 | $-2.16 | $-0.61 | $-0.27 | $0.38 | $-0.23 | $0.25 | $-0.31 |
| EPS (Diluted) | $-0.60 | $-2.16 | $-0.59 | $-0.27 | $0.36 | $-0.23 | $0.25 | $-0.31 |
| Shares Outstanding (Basic) | 29.7M | 29.3M | 28.6M | 28.8M | 28.6M | 28.1M | 26.9M | 27.1M |
| Shares Outstanding (Diluted) | 29.7M | 29.3M | 28.6M | 28.8M | 29.8M | 28.1M | 26.9M | 27.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |